Skip to main content
SpringerLink
Log in

Neuropsychopharmacotherapy: Differential Doses Regimes in China

  • Living reference work entry
  • First Online:
NeuroPsychopharmacotherapy

  • 153 Accesses

Abstract

Prescription habits are affected by a variety of factors, including the healthcare system, financing schemes, medical traditions, consumers’ choices, and the overall sociocultural background of the respective countries. In the treatment of psychosis, many Western countries have published national guidelines or consensus statements that refer to the prescribing of neuropsychopharmacotherapy. All advise against the use of high dosage other than in exceptional circumstances. However, there are discrepancies between these guidelines or algorithms and prescription patterns and that practice varies substantially according to patient, prescriber, and institution.

The present chapter aimed to assess the prescription patterns of psychotropic drugs for patients with psychosis in China and to determine factors affecting their prescriptions, especially the situation of antipsychotic polypharmacy in China.

Clozapine remains one of the most commonly used antipsychotic medications in China. As China has the largest population internationally on clozapine treatment, its experience and research findings are of keen interest to Western psychiatrists. Here, it was systematically introduced clozapine use in China, including brief history, prevalence of clozapine use, product Information, and pattern of utilization of clozapine.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Abel KM, Drake R, Goldstein JM. Sex differences in schizophrenia. Int Rev Psychiatry. 2010;22:417–28.

    Article  PubMed  Google Scholar 

  • Aitchison KJ, Kerwin RW. Cost-effectiveness of clozapine. A UK clinic-based study. Br J Psychiatry. 1997;171:125–30.

    Article  CAS  PubMed  Google Scholar 

  • Amsler HA, Teerenhovi L, Barth E, Harjula K, Vuopio P. Agranulocytosis in patients treated with clozapine. A study of the Finnish epidemic. Acta Psychiatr Scand. 1977;56:241–8.

    Article  CAS  PubMed  Google Scholar 

  • Bai Z, Wang G, Cai S, Ding X, Liu W, Huang D, Shen W, Zhang J, Chen K, Yang Y, Zhang L, Zhao X, Ouyang Q, Zhao J, Lu H, Hao W. Efficacy, acceptability and tolerability of 8 atypical antipsychotics in Chinese patients with acute schizophrenia: a network meta-analysis. Schizophr Res. 2017;185:73–9.

    Article  PubMed  Google Scholar 

  • Barnes TR, Schizophrenia Consensus Group of British Association for Psychopharmacology. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2011;25: 567–620.

    Article  CAS  PubMed  Google Scholar 

  • Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, Himelhoch S, Fang B, Peterson E, Aquino PR, Keller W, Schizophrenia Patient Outcomes Research Team. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36:71–93.

    Article  PubMed  Google Scholar 

  • Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4:28–37.

    Google Scholar 

  • Carbon M, Correll CU. Clinical predictors of therapeutic response to antipsychotics in schizophrenia. Dialogues Clin Neurosci. 2014;16:505–24.

    PubMed  PubMed Central  Google Scholar 

  • Chinese Medical Association. Guideline for the prevention and treatment of psychiatric disorders in China. Beijing: Chinese Medical Association; 2003.

    Google Scholar 

  • Chong MY, Tan CH, Fujii S, Yang SY, Ungvari GS, Si T, Chung EK, Sim K, Tsang HY, Shinfuku N. Antipsychotic drug prescription for schizophrenia in East Asia: rationale for change. Psychiatry Clin Neurosci. 2004;58:61–7.

    Article  PubMed  Google Scholar 

  • Conley RR, Buchanan RW. Evaluation of treatment-resistant schizophrenia. Schizophr Bull. 1997;23:663–74.

    Article  CAS  PubMed  Google Scholar 

  • Conley RR, Kelly DL, Richardson CM, Tamminga CA, Carpenter WT Jr. The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study. J Clin Psychopharmacol. 2003;23:668–71.

    Article  CAS  PubMed  Google Scholar 

  • Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004; 161:414–25.

    Article  PubMed  Google Scholar 

  • Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull. 2009;35:443–57.

    Article  PubMed  Google Scholar 

  • Esposito D, Rouillon F, Limosin F. Continuing clozapine treatment despite neutropenia. Eur J Clin Pharmacol. 2005;60:759–64.

    Article  CAS  PubMed  Google Scholar 

  • Essali A, Al-Haj Haasan N, Li C, Rathbone J. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev. 2009;1:CD000059.

    Google Scholar 

  • Fernandez HH, Donnelly EM, Friedman JH. Long-term outcome of clozapine use for psychosis in parkinsonian patients. Mov Disord. 2004;19:831–3.

    Article  PubMed  Google Scholar 

  • Gallego JA, Nielsen J, De Hert M, Kane JM, Correll CU. Safety and tolerability of antipsychotic polypharmacy. Expert Opin Drug Saf. 2012;11:527–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Galling B, Roldan A, Hagi K, Rietschel L, Walyzada F, Zheng W, Cao XL, Xiang YT, Zink M, Kane JM, Nielsen J, Leucht S, Correll CU. Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. World Psychiatry. 2017;16:77–89.

    Article  PubMed  PubMed Central  Google Scholar 

  • Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin BC. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998–2000. J Clin Psychiatry. 2004;65:1377–88.

    Article  PubMed  Google Scholar 

  • Haro JM, Salvador-Carulla L. The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia. CNS Drugs. 2006;20:293–301.

    Article  CAS  PubMed  Google Scholar 

  • Henderson DC, Goff DC. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. J Clin Psychiatry. 1996;57:395–7.

    CAS  PubMed  Google Scholar 

  • Hippius H. A historical perspective of clozapine. J Clin Psychiatry. 1999;60(Suppl 12):22–3.

    PubMed  Google Scholar 

  • Honer WG, Thornton AE, Chen EY, Chan RC, Wong JO, Bergmann A, Falkai P, Pomarol-Clotet E, Mckenna PJ, Stip E, Williams R, Macewan GW, Wasan K, Procyshyn R, Clozapine and Risperidone Enhancement Study Group. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med. 2006;354:472–82.

    Article  CAS  PubMed  Google Scholar 

  • Honigfeld G, Arellano F, Sethi J, Bianchini A, Schein J. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry. 1998; 59(Suppl 3):3–7.

    PubMed  Google Scholar 

  • Hou CL, Ma XR, Zang Y, Jia FJ, Lin YQ, Chiu HF, Ungvari GS, Ng CH, Zhong BL, Cao XL, Li Y, Cai MY, Xiang YT. Antipsychotic polypharmacy and quality of life in patients with schizophrenia treated in primary care in China. Int J Clin Pharmacol Ther. 2016;54:36–42.

    Article  CAS  PubMed  Google Scholar 

  • Hou CL, Wang SB, Wang F, Xu MZ, Chen MY, Cai MY, Xiao YN, Jia FJ. Psychotropic medication treatment patterns in community-dwelling schizophrenia in China: comparisons between rural and urban areas. BMC Psychiatry. 2019;19:242.

    Article  PubMed  PubMed Central  Google Scholar 

  • Howes OD, Vergunst F, Gee S, Mcguire P, Kapur S, Taylor D. Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry. 2012;201:481–5.

    Article  PubMed  Google Scholar 

  • Ifteni P, Correll CU, Nielsen J, Burtea V, Kane JM, Manu P. Rapid clozapine titration in treatment-refractory bipolar disorder. J Affect Disord. 2014;166:168–72.

    Article  CAS  PubMed  Google Scholar 

  • Iqbal MM, Rahman A, Husain Z, Mahmud SZ, Ryan WG, Feldman JM. Clozapine: a clinical review of adverse effects and management. Ann Clin Psychiatry. 2003;15:33–48.

    Article  PubMed  Google Scholar 

  • Ito H, Okumura Y, Higuchi T, et al. International variation in antipsychotic prescribing for schizophrenia: pooled results from the research on East Asia psychotropic prescription (REAP) studies. Open J Psychiatry. 2012;2:340–6.

    Article  Google Scholar 

  • Jeon SW, Kim YK. Unresolved issues for utilization of atypical antipsychotics in schizophrenia: antipsychotic polypharmacy and metabolic syndrome. Int J Mol Sci. 2017;18:2174.

    Article  PubMed Central  CAS  Google Scholar 

  • Josiassen RC, Joseph A, Kohegyi E, Stokes S, Dadvand M, Paing WW, Shaughnessy RA. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2005;162:130–6.

    Article  PubMed  Google Scholar 

  • Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789–96.

    Article  CAS  PubMed  Google Scholar 

  • Kapur S, Roy P, Daskalakis J, Remington G, Zipursky R. Increased dopamine d(2) receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine. Am J Psychiatry. 2001;158:311–4.

    Article  CAS  PubMed  Google Scholar 

  • Kochi K, Sato I, Nishiyama C, Tanaka-Mizuno S, Doi Y, Arai M, Fujii Y, Matsunaga T, Ogawa Y, Furukawa TA, Kawakami K. Trends in antipsychotic prescriptions for Japanese outpatients during 2006–2012: a descriptive epidemiological study. Pharmacoepidemiol Drug Saf. 2017;26:642–56.

    Article  CAS  PubMed  Google Scholar 

  • Krakowski MI, Czobor P, Citrome L, Bark N, Cooper TB. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2006;63:622–9.

    Article  CAS  PubMed  Google Scholar 

  • Kuno E, Rothbard AB. Racial disparities in antipsychotic prescription patterns for patients with schizophrenia. Am J Psychiatry. 2002;159:567–72.

    Article  PubMed  Google Scholar 

  • Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lassig B, Salanti G, Davis JM. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951–62.

    Article  CAS  PubMed  Google Scholar 

  • Li Q, Xiang YT, Su YA, Shu L, Yu X, Chiu HF, Correll CU, Ungvari GS, Lai KY, Ma C, Wang GH, Bai PS, Li T, Sun LZ, Shi JG, Chen XS, Mei QY, Li KQ, Si TM. Antipsychotic polypharmacy in schizophrenia patients in China and its association with treatment satisfaction and quality of life: findings of the third national survey on use of psychotropic medications in China. Aust N Z J Psychiatry. 2015a;49:129–36.

    Article  CAS  PubMed  Google Scholar 

  • Li Q, Xiang YT, Su YA, Shu L, Yu X, Correll CU, Ungvari GS, Chiu HF, Ma C, Wang GH, Bai PS, Li T, Sun LZ, Shi JG, Chen XS, Mei QY, Li KQ, Si TM, Kane JM. Clozapine in schizophrenia and its association with treatment satisfaction and quality of life: findings of the three national surveys on use of psychotropic medications in China (2002–2012). Schizophr Res. 2015b; 168:523–9.

    Article  PubMed  Google Scholar 

  • Li XH, Zhong XM, Lu L, Zheng W, Wang SB, Rao WW, Wang S, Ng CH, Ungvari GS, Wang G, Xiang YT. The prevalence of agranulocytosis and related death in clozapine-treated patients: a comprehensive meta-analysis of observational studies. Psychol Med. 2019;12:1–12.

    Google Scholar 

  • Lieberman JA, Kane JM, Johns CA. Clozapine: guidelines for clinical management. J Clin Psychiatry. 1989;50:329–38.

    CAS  PubMed  Google Scholar 

  • Lin CH, Lin CY, Wang HS, Lane HY. Long-term use of clozapine is protective for bone density in patients with schizophrenia. Sci Rep. 2019;9:3895.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Liu TL, Li CY. The comparison of use of antipsychotics in first-episode patients with schizophrenia (in Chinese). Med J Chin People Health. 2003;15:289–90.

    Google Scholar 

  • Lung SLM, Lee HME, Chen YHE, Chan KWS, Chang WC, Hui LMC. Prevalence and correlates of antipsychotic polypharmacy in Hong Kong. Asian J Psychiatr. 2018;33:113–20.

    Article  PubMed  Google Scholar 

  • Maccall C, Billcliff N, Igbrude W, Natynczuk S, Spencer EP, Flanagan RJ. Clozapine: more than 900 mg/day may be needed. J Psychopharmacol. 2009;23:206–10.

    Article  CAS  PubMed  Google Scholar 

  • Malalagama G, Bastiampillai T, Dhillon R. Clozapine prescription patterns in Australia over the last 10 years. Aust N Z J Psychiatry. 2011;45:498–9.

    Article  PubMed  Google Scholar 

  • Mao PX, Tang YL, Wang ZM, Jiang F, Gillespie CF, Cai ZJ. Antipsychotic drug use in 503 Chinese inpatients with schizophrenia. Int J Psychiatry Clin Pract. 2007;11:29–35.

    Article  CAS  PubMed  Google Scholar 

  • Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, Bourgeois M, Chouinard G, Islam MZ, Kane J, Krishnan R, Lindenmayer JP, Potkin S, International Suicide Prevention Trial Study Group. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry. 2003;60:82–91.

    Article  CAS  PubMed  Google Scholar 

  • Miyamoto S, Jarskog LF, Fleischhacker WW. New therapeutic approaches for treatment-resistant schizophrenia: a look to the future. J Psychiatr Res. 2014;58:1–6.

    Article  PubMed  Google Scholar 

  • Miyamoto S, Jarskog LF, Fleischhacker WW. Schizophrenia: when clozapine fails. Curr Opin Psychiatry. 2015;28:243–8.

    Article  PubMed  Google Scholar 

  • Moore TA, Buchanan RW, Buckley PF, Chiles JA, Conley RR, Crismon ML, Essock SM, Finnerty M, Marder SR, Miller DD, Mcevoy JP, Robinson DG, Schooler NR, Shon SP, Stroup TS, Miller AL. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry. 2007;68:1751–62.

    Article  CAS  PubMed  Google Scholar 

  • Morrato EH, Dodd S, Oderda G, Haxby DG, Allen R, Valuck RJ. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998–2003. Clin Ther. 2007;29:183–95.

    Article  CAS  PubMed  Google Scholar 

  • Mustafa FA, Burke JG, Abukmeil SS, Scanlon JJ, Cox M. “Schizophrenia past clozapine”: reasons for clozapine discontinuation, mortality, and alternative antipsychotic prescribing. Pharmacopsychiatry. 2015;48:11–4.

    CAS  PubMed  Google Scholar 

  • Ng CH, Chong SA, Lambert T, Fan A, Hackett LP, Mahendran R, Subramaniam M, Schweitzer I. An inter-ethnic comparison study of clozapine dosage, clinical response and plasma levels. Int Clin Psychopharmacol. 2005;20:163–8.

    Article  PubMed  Google Scholar 

  • Nielsen J, Dahm M, Lublin H, Taylor D. Psychiatrists’ attitude towards and knowledge of clozapine treatment. J Psychopharmacol. 2010;24:965–71.

    Article  CAS  PubMed  Google Scholar 

  • Nielsen J, Damkier P, Lublin H, Taylor D. Optimizing clozapine treatment. Acta Psychiatr Scand. 2011;123:411–22.

    Article  CAS  PubMed  Google Scholar 

  • Nielsen J, Kane JM, Correll CU. Real-world effectiveness of clozapine in patients with bipolar disorder: results from a 2-year mirror-image study. Bipolar Disord. 2012a;14:863–9.

    Article  CAS  PubMed  Google Scholar 

  • Nielsen J, Nielsen RE, Correll CU. Predictors of clozapine response in patients with treatment-refractory schizophrenia: results from a Danish Register Study. J Clin Psychopharmacol. 2012b;32:678–83.

    Article  CAS  PubMed  Google Scholar 

  • Nielsen J, Young C, Ifteni P, Kishimoto T, Xiang YT, Schulte PF, Correll CU, Taylor D. Worldwide differences in regulations of clozapine use. CNS Drugs. 2016;30:149–61.

    Article  PubMed  Google Scholar 

  • Percudani M, Barbui C, Fortino I, Petrovich L. Epidemiology of first- and second-generation antipsychotic agents in Lombardy, Italy. Pharmacopsychiatry. 2005;38:128–31.

    Article  CAS  PubMed  Google Scholar 

  • Phillips MR, Lu SH, Wang RW. Economic reforms and the acute inpatient care of patients with schizophrenia: the Chinese experience. Am J Psychiatry. 1997;154:1228–34.

    Article  CAS  PubMed  Google Scholar 

  • Potter WZ, Ko GN, Zhang LD, Yan WW. Clozapine in China: a review and preview of US/PRC collaboration. Psychopharmacology (Berl). 1989;99(Suppl):S87–91.

    Article  Google Scholar 

  • Qiu H, He Y, Zhang Y, He M, Liu J, Chi R, Si T, Wang H, Dong W. Antipsychotic polypharmacy in the treatment of schizophrenia in China and Japan. Aust N Z J Psychiatry. 2018. https://doi.org/10.1177/0004867418805559.

    Article  Google Scholar 

  • Remington G, Saha A, Chong SA, Shammi C. Augmentation strategies in clozapine-resistant schizophrenia. CNS Drugs. 2005;19:843–72.

    Article  CAS  PubMed  Google Scholar 

  • Rothbard AB, Kuno E, Foley K. Trends in the rate and type of antipsychotic medications prescribed to persons with schizophrenia. Schizophr Bull. 2003;29:531–40.

    Article  PubMed  Google Scholar 

  • Ruan CJ, De Leon J. Thirty years of both ignorance and clinical experience suggest that clozapine intoxication during co-occurring infections and inflammation may have higher morbidity and mortality than is currently believed. Psychosomatics. 2019;60:221–2.

    Article  PubMed  Google Scholar 

  • Ruan CJ, Zhang XL, Guo W, Li WB, Zhuang HY, Li YQ, Wang CY, Tang YL, Zhou FC, De Leon J. Two cases of high serum clozapine concentrations occurring during inflammation in Chinese patients. Int J Psychiatry Med. 2018;53:292–305.

    Article  PubMed  Google Scholar 

  • Schulte P. What is an adequate trial with clozapine?: therapeutic drug monitoring and time to response in treatment-refractory schizophrenia. Clin Pharmacokinet. 2003;42:607–18.

    Article  CAS  PubMed  Google Scholar 

  • Shiloh R, Zemishlany Z, Aizenberg D, Radwan M, Schwartz B, Dorfman-Etrog P, Modai I, Khaikin M, Weizman A. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. Br J Psychiatry. 1997;171:569–73.

    Article  CAS  PubMed  Google Scholar 

  • Si TM, Shu L, Yu X, Ma C, Wang GH, Pai PS, Liu XH, Ji LP, Shi JG, Chen XS, Mei QY, Li KQ, Zhang HY, Ma H. Antipsychotic drug patterns of schizophrenia in China: a cross-sectional study (in Chinese). Chin J Psychiatry. 2004;37:152–5.

    Google Scholar 

  • Sim K, Su A, Chan YH, Shinfuku N, Kua EH, Tan CH. Clinical correlates of antipsychotic polytherapy in patients with schizophrenia in Singapore. Psychiatry Clin Neurosci. 2004; 58:324–9.

    Article  PubMed  Google Scholar 

  • Stip E, Yan H, Lee P. Clozapine in a Chinese population. J Psychiatry Neurosci Bull. 1996; 21:283–4.

    CAS  Google Scholar 

  • Tang YL. Pharmacotherapy of schizophrenia. In: Cai ZJ, Weng YZ, Tang YL, editors. Schizophrenia: from biology to treatments (Chinese). 1st ed. Beijing: The Science Press; 2000. p. 214–27.

    Google Scholar 

  • Tang YL, Mao PX, Jiang F, Chen Q, Wang CY, Cai ZJ, Mitchell PB. Clozapine in China. Pharmacopsychiatry. 2008;41:1–9.

    Article  CAS  PubMed  Google Scholar 

  • Ungvari GS, Chow LY, Chiu HF, Ng FS, Leung T. Modifying psychotropic drug prescription patterns: a follow-up survey. Psychiatry Clin Neurosci. 1997;51:309–14.

    Article  CAS  PubMed  Google Scholar 

  • Wang CY, Xiang YT, Cai ZJ, Weng YZ, Bo QJ, Zhao JP, Liu TQ, Wang GH, Weng SM, Zhang HY, Chen DF, Tang WK, Ungvari GS, Risperidone Maintenance Treatment in Schizophrenia Investigators. Risperidone maintenance treatment in schizophrenia: a randomized, controlled trial. Am J Psychiatry. 2010;167:676–85.

    Article  PubMed  Google Scholar 

  • Xiang YT, Weng YZ, Leung CM, Tang WK, Ungvari GS. Clinical correlates of clozapine prescription for schizophrenia in China. Hum Psychopharmacol. 2007;22:17–25.

    Article  CAS  PubMed  Google Scholar 

  • Xiang YT, Wang CY, Si TM, Lee EH, He YL, Ungvari GS, Chiu HF, Shinfuku N, Yang SY, Chong MY, Kua EH, Fujii S, Sim K, Yong MK, Trivedi JK, Chung EK, Udomratn P, Chee KY, Sartorius N, Dixon LB, Kreyenbuhl JA, Tan CH. Clozapine use in schizophrenia: findings of the Research on Asia Psychotropic Prescription (REAP) studies from 2001 to 2009. Aust N Z J Psychiatry. 2011;45:968–75.

    Article  PubMed  Google Scholar 

  • Xiang YT, Wang CY, Si TM, Lee EH, He YL, Ungvari GS, Chiu HF, Yang SY, Chong MY, Tan CH, Kua EH, Fujii S, Sim K, Yong KH, Trivedi JK, Chung EK, Udomratn P, Chee KY, Sartorius N, Shinfuku N. Antipsychotic polypharmacy in inpatients with schizophrenia in Asia (2001–2009). Pharmacopsychiatry. 2012;45:7–12.

    Article  CAS  PubMed  Google Scholar 

  • Xiang YT, Buchanan RW, Ungvari GS, Chiu HF, Lai KY, Li YH, Si TM, Wang CY, Lee EH, He YL, Yang SY, Chong MY, Kua EH, Fujii S, Sim K, Yong MK, Trivedi JK, Chung EK, Udomratn P, Chee KY, Sartorius N, Tan CH, Shinfuku N. Use of clozapine in older Asian patients with schizophrenia between 2001 and 2009. PLoS One. 2013;8:e66154.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Xu SW, Dong M, Zhang Q, Yang SY, Chen LY, Sim K, He YL, Chiu HF, Sartorius N, Tan CH, Chong MY, Shinfuku N, Lin SK, Ng CH, Ungvari GS, Najoan E, Kallivayalil RA, Jamaluddin R, Javed A, Iida H, Swe T, Zhang B, Xiang YT. Clozapine prescription pattern in patients with schizophrenia in Asia: the REAP survey (2016). Psychiatry Res. 2019.

    Google Scholar 

  • Yang HC, Yang KJ, Liu TB, Gao H, Lu YW. The clinical characteristics of patients with treatment-resistant schizophrenia. Med J Chin People’s Health. 2005;17:257–9.

    Google Scholar 

  • Ye M, Tang W, Liu L, Zhang F, Liu J, Chen Y, Chen DC, Tan YL, Yang FD, Hong Xiu M, Hui L, Lv MH, Soares JC, Zhang XY. Prevalence of tardive dyskinesia in chronic male inpatients with schizophrenia on long-term clozapine versus typical antipsychotics. Int Clin Psychopharmacol. 2014;29:318–21.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Mental Health, Tianjin Anding Hospital, Tianjin, China

    Jie Li

  2. Department of Psychiatry, Tianjin Medical University, Tianjin, China

    Shen Li

Authors
  1. Jie Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shen Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jie Li .

Editor information

Editors and Affiliations

  1. Dept Psychiatry , Psychosomatics & Psychotherapy, University of WĂĽrzburg, Medical School Clinical Neurochemistry, WĂĽrzburg, Germany

    Peter Riederer

  2. Inst fĂĽr Psychologische Medizin, Haag, Bayern, Germany

    Gerd Laux

  3. Department of Psychiatry, University of Toronto Department of Psychiatry, Toronto, ON, Canada

    Benoit Mulsant

  4. Center Translational Res Neurol Diseases, Dalian Med Uni Shanghai Inst Health Sc Center Translational Res Neurol Diseases, Dalian, China

    Weidong Le

  5. Fujita Health University School Medicine, Toyoake, Aichi, Japan

    Toshiharu Nagatsu

Section Editor information

  1. University Hospital, Center for Mental Health, Clinic and Policlinic for Psychiatry, Psychosomatics and Psychotherapy, University Wuerzburg, Wuerzburg, Germany

    Peter Riederer

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Li, J., Li, S. (2020). Neuropsychopharmacotherapy: Differential Doses Regimes in China. In: Riederer, P., Laux, G., Mulsant, B., Le, W., Nagatsu, T. (eds) NeuroPsychopharmacotherapy. Springer, Cham. https://doi.org/10.1007/978-3-319-56015-1_22-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-56015-1_22-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-56015-1

  • Online ISBN: 978-3-319-56015-1

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation